These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: Reversion of tumorigenicity in an EBV-converted Burkitt's lymphoma line.
    Author: Klein G.
    Journal: Ciba Found Symp; 1989; 142():36-48; discussion 48-53. PubMed ID: 2545422.
    Abstract:
    One of five Epstein-Barr virus (EBV)-converted sublines of an EBV-negative Burkitt's lymphoma line (BL-41) was identified as a non-tumorigenic phenotypic revertant with low clonability, comparable to that of an EBV-transformed lymphoblastoid cell line (IARC-171) derived from the same patient. This revertant subline (BL-41/95) also showed the most LCL-like phenotype of the five convertants tested. It is suggested that reversion was due to the phenotypic shift of the cell from a 'window' of cell ontogeny that contains virgin B cells and memory B cells to the stage of the activated immunoblast. Constitutive activation of the c-myc gene by translocation to an immunoglobulin locus continues to drive proliferation of B cells in vivo even after they have undergone a programmed switch to a basically resting (virgin or memory cell) phenotype. An activated immunoblast invariably expresses c-myc. It is also suggested that proliferation of the activated immunoblast is regulated by negative host controls that prevent clonal overexpansion and keep the B cell pool constant. The sensitivity of the immunoblast to this control overrides the 'forward-driving' force of both EBV and the activated myc gene.
    [Abstract] [Full Text] [Related] [New Search]